LIFE SAVING DRUGS PROGRAM EXPERT PANEL

21st MEETING: 25 JULY 2025

**AGENDA**

1. **Standing business**
   1. Welcome, apologies and Conflicts of Interest
   2. Update on actions from previous meetings
   3. Correspondence
   4. Report from the secretariat
2. **24 month review of existing LSDP medicines**
   1. Avalglucosidase alfa (Nexviazyme®) – for the treatment of Pompe disease
   2. Consideration of future 24 month reviews
3. **Applications for new LSDP medicines**
   1. Cipaglucosidase alfa (Pombiliti®) + miglustat (Opfolda®) for the treatment of late onset Pompe disease
4. **Other business**